Update: Preparing to go solo in the US on aldoxorubicin
As it advances lead candidate aldoxorubicin through clinical trials, CytRx is also planning to commercialise the oncology drug through a specialty sales force in the US, rather than go through traditional biotech drug out-licensing deals in this market. We are revising our assumptions to consider the prospect of CytRx capturing full US aldoxorubicin economics, which raises our rNPV to $375m (from $209m previously).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.